On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression

On the day after the FDA blessed Sage Therapeutics $SAGE with its inside track on their oral depression drug SAGE-217, Japan’s Shionogi has stepped in with a $575 million deal to gather up limited Asian rights to the drug.